Biohaven Ltd.
BHVNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Biohaven Ltd. (BHVN) is listed under Biotechnology. Valued at $2.10B, BHVN is a mid-cap name in its sector. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Market Cap
$2.10B
Beta
3.20
P/E (TTM)
—
P/E (Fwd)
-7.98
EPS (TTM)
$-4.56
EPS (Fwd)
$-1.74
ROE
-799.5%
ROA
-72.0%
Cash
$267.9M
Total Debt
$297.0M
Free CF
-$256.2M
52W Change
-16.4%
Annual Financials
Cash vs Debt
Where BHVN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BHVN finished 7.65% below its 150-day moving average ($12.29) and 6.04% below its 200-day moving average ($12.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BHVN overbought or oversold?
At the October 20, 2026 close, BHVN's RSI(14) was 29.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BHVN has $267.9M in cash with $297.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$256.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -799.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, BHVN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biohaven Ltd. and its sector.